S. Nagel

Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.

C. Schumann, W. Engel-Riedel, S. Guetz, 2011, Clinical lung cancer.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

A. Reissig, M. Serke, E. Schmidt, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-1 A phase III trial comparing weekly and three weekly docetaxel in second line treatment of patients with advanced non small cell lung cancer (NSCLC)

M. Serke, W. Schuette, S. Nagel, 2003 .

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

T. Blankenburg, W. Schuette, S. Nagel, 2014, Case Reports in Oncology.

Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.

P. Lorigan, F. Blackhall, N. Thatcher, 2006, Lung cancer.

Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study

M. Serke, W. Schuette, S. Nagel, 2004 .

Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study.

M. Serke, W. Schuette, S. Nagel, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.

T. Blankenburg, W. Schuette, S. Nagel, 2005, Clinical lung cancer.

Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

F. Blackhall, N. Thatcher, R. Califano, 2007, Expert opinion on pharmacotherapy.

Clinical Benefit in NSCLC: Advanced-Stage Patients Require Symptom-Improving Palliation. Experiences from the ‘Iressa’ Expanded Access Program

T. Blankenburg, W. Schuette, S. Nagel, 2005, Oncology Research and Treatment.

Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung Cancer: The APRONTA Trial

C. Schumann, N. Dickgreber, W. Schuette, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).

C. Schumann, C. Kortsik, M. Reck, 2013 .